Matinas BioPharma Holdings, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 04 Sep 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 26 Jun 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 03 Apr 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Matinas BioPharma Holdings, Inc. — Overview & Financial Snapshot
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a Healthcare company, ranked #1,758 of 6,774 companies globally and #434 of 4,000 in United States on PositoAI, with a Positivity Score of 22,340. Its market capitalisation is ₹15.81 Cr ($1.67M), P/E ratio is -0.1 and P/B ratio is 0.93. It currently has 3 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →